131 related articles for article (PubMed ID: 36472350)
1. Influence of Preservatives on Insulin in Postmortem Blood: Application to a Case of Insulin Aspart Suicide.
Arbouche N; Macoin E; Raul JS; Kintz P
J Anal Toxicol; 2023 Jan; 46(9):e300-e306. PubMed ID: 36472350
[TBL] [Abstract][Full Text] [Related]
2. Attempted Murder of a Young Child Followed by an Attempted Suicide of the Mother by Injection of Insulin Aspart: Identification of Quantification of Insulin by LC-HRMS and UPLC-MS/MS in Blood of the Two Cases.
Arbouche N; Godard E; Gheddar L; Raul JS; Kintz P
J Anal Toxicol; 2021 Sep; ():. PubMed ID: 34529061
[TBL] [Abstract][Full Text] [Related]
3. Fast-acting insulin aspart (Fiasp®) improves glycemic outcomes when used with MiniMed
Grosman B; Wu D; Parikh N; Roy A; Voskanyan G; Kurtz N; Sturis J; Cohen O; Ekelund M; Vigersky R
Comput Methods Programs Biomed; 2021 Jun; 205():106087. PubMed ID: 33873075
[TBL] [Abstract][Full Text] [Related]
4. [Faster aspart insulin (FIASP®)].
Paquot N; Scheen AJ
Rev Med Liege; 2018 Apr; 73(4):211-215. PubMed ID: 29676875
[TBL] [Abstract][Full Text] [Related]
5. Spotlight on insulin aspart in type 1 and 2 diabetes mellitus.
Chapman TM; Noble S; Goa KL
Treat Endocrinol; 2003; 2(1):71-6. PubMed ID: 15871555
[TBL] [Abstract][Full Text] [Related]
6. Fast-Acting Insulin Aspart Use with the MiniMed
Hsu L; Buckingham B; Basina M; Ekhlaspour L; von Eyben R; Wang J; Lal RA
Diabetes Technol Ther; 2021 Jan; 23(1):1-7. PubMed ID: 32520594
[No Abstract] [Full Text] [Related]
7. In vitro Stability of Biosimilar Insulin Aspart SAR341402 in the Medtronic MiniMed Insulin Pumps.
Mohnicke M; Blecher A; Beichert K; Bidlingmaier B; Todt EJ; Dette C; Rotthaeuser B; Mukherjee B
J Pharm Sci; 2023 Apr; 112(4):963-973. PubMed ID: 36521561
[TBL] [Abstract][Full Text] [Related]
8. Efficacy and Safety of Insulin Aspart Biosimilar SAR341402 Versus Originator Insulin Aspart in People with Diabetes Treated for 26 Weeks with Multiple Daily Injections in Combination with Insulin Glargine: A Randomized Open-Label Trial (GEMELLI 1).
Garg SK; Wernicke-Panten K; Wardecki M; Kramer D; Delalande F; Franek E; Sadeharju K; Monchamp T; Mukherjee B; Shah VN
Diabetes Technol Ther; 2020 Feb; 22(2):85-95. PubMed ID: 31804851
[No Abstract] [Full Text] [Related]
9. Pump Users Clamor for Faster Insulin: Is Fast-Acting Insulin Aspart Ready for Them?
Muchmore DB
J Diabetes Sci Technol; 2018 Jan; 12(1):152-154. PubMed ID: 29291651
[TBL] [Abstract][Full Text] [Related]
10. Comparable Glucose Control with Fast-Acting Insulin Aspart Versus Insulin Aspart Using a Second-Generation Hybrid Closed-Loop System During Exercise.
Morrison D; Zaharieva DP; Lee MH; Paldus B; Vogrin S; Grosman B; Roy A; Kurtz N; O'Neal DN
Diabetes Technol Ther; 2022 Feb; 24(2):93-101. PubMed ID: 34524022
[No Abstract] [Full Text] [Related]
11. Insulin aspart: a review of its use in the management of type 1 or 2 diabetes mellitus.
Reynolds NA; Wagstaff AJ
Drugs; 2004; 64(17):1957-74. PubMed ID: 15329046
[TBL] [Abstract][Full Text] [Related]
12. Single-Dose Euglycemic Clamp Study Demonstrating Pharmacokinetic and Pharmacodynamic Similarity Between SAR341402 Insulin Aspart and US- and EU-Approved Versions of Insulin Aspart in Subjects with Type 1 Diabetes.
Kapitza C; Nosek L; Schmider W; Teichert L; Nowotny I
Diabetes Technol Ther; 2020 Apr; 22(4):278-284. PubMed ID: 31825248
[No Abstract] [Full Text] [Related]
13. Fast Acting Insulin Aspart Compared with Insulin Aspart in the Medtronic 670G Hybrid Closed Loop System in Type 1 Diabetes: An Open Label Crossover Study.
Ozer K; Cooper AM; Ahn LP; Waggonner CR; Blevins TC
Diabetes Technol Ther; 2021 Apr; 23(4):286-292. PubMed ID: 33090016
[TBL] [Abstract][Full Text] [Related]
14. Fast-Acting Insulin Aspart and the Need for New Mealtime Insulin Analogues in Adults With Type 1 and Type 2 Diabetes: A Canadian Perspective.
Senior P; Hramiak I
Can J Diabetes; 2019 Oct; 43(7):515-523. PubMed ID: 30872107
[TBL] [Abstract][Full Text] [Related]
15. In Vitro Biological Characterization of Recombinant Insulin Aspart from Biogenomics and Originator Insulin Aspart.
Mishra AG; Deshmane RB; Thappa DK; Lona J; Ghade NS; Sonar SM; Krishnan AR
BioDrugs; 2023 Sep; 37(5):709-719. PubMed ID: 37285012
[TBL] [Abstract][Full Text] [Related]
16. Hybrid closed-loop glucose control with faster insulin aspart compared with standard insulin aspart in adults with type 1 diabetes: A double-blind, multicentre, multinational, randomized, crossover study.
Boughton CK; Hartnell S; Thabit H; Poettler T; Herzig D; Wilinska ME; Ashcroft NL; Sibayan J; Cohen N; Calhoun P; Bally L; Mader JK; Evans M; Leelarathna L; Hovorka R
Diabetes Obes Metab; 2021 Jun; 23(6):1389-1396. PubMed ID: 33606901
[TBL] [Abstract][Full Text] [Related]
17. Safety, Immunogenicity, and Glycemic Control of Insulin Aspart Biosimilar SAR341402 Versus Originator Insulin Aspart in People with Diabetes Also Using Insulin Glargine: 12-Month Results from the GEMELLI 1 Trial.
Garg SK; Wernicke-Panten K; Wardecki M; Kramer D; Delalande F; Franek E; Sadeharju K; Monchamp T; Miossec P; Mukherjee B; Shah VN
Diabetes Technol Ther; 2020 Jul; 22(7):516-526. PubMed ID: 32068436
[No Abstract] [Full Text] [Related]
18. [Pharmacological and clinical characteristics of Insulin Faster Aspart (Fiasp®)].
Faingold MC; Luquez C; Oviedo A; Puchulu F; Re M
Medicina (B Aires); 2022; 82(5):752-759. PubMed ID: 36220033
[TBL] [Abstract][Full Text] [Related]
19. [Intensified insulin therapy of type 2 diabetes mellitus: pre- or postprandial injection of aspart insulin?].
Jungmann E
Dtsch Med Wochenschr; 2005 May; 130(20):1254-7. PubMed ID: 15889321
[TBL] [Abstract][Full Text] [Related]
20. Improved glycemic control with insulin aspart: a multicenter randomized double-blind crossover trial in type 1 diabetic patients. UK Insulin Aspart Study Group.
Home PD; Lindholm A; Hylleberg B; Round P
Diabetes Care; 1998 Nov; 21(11):1904-9. PubMed ID: 9802741
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
